Estar Medical, the maker of Eclipse PRP® and Tropocells®, has signed an exclusive long-term marketing and distribution agreement with Aesthetic Management Partners, LLC (AMP), to sell its PRP products in the U.S. market.
The agreement joins AMP, a medical device and biologics company, with Israel- and U.K.-based Estar Medical, a provider in platelet-rich plasma (PRP) and other related cell therapies and technologies. With the execution of this agreement, Estar Medical’s PRP, currently sold throughout the world, will now be sold in the U.S. under its global brand name: Cellenis®.
For Estar Medical, partnering with AMP provides a proven and growing distribution team in North America to launch the Cellenis Platelet Rich Plasma (PRP) brand, company officials say. This aligns with Estar Medical’s mission to grow the Cellenis brand globally.
“Our unique 11 and 22ml PRP tubes have become the gold standard PRP in the U.S. for many indications within the regenerative medicine field,” says Aaron Esteron, CEO and founder of Estar Medical. “These PRP products will now be sold exclusively under our global Cellenis brand and will continue to generate positive results among physicians and key opinion leaders, delivering superior results for their patients.”
Esteron adds, “The expansion of the Cellenis brand into the U.S. and the collaboration with AMP represents a key step forward in our global expansion strategy and one that will further strengthen our relationships with healthcare providers as our unique and proven PRP technology has already become their preferred choice in the U.S. This is truly a synergistic partnership that creates value as well as future opportunities for our Cellenis existing products and pipeline.”
Erik Dowell, CEO and founder of AMP, also spoke out about the partnership, saying he’s excited to launch the Cellenis PRP line in the U.S. “We are proud to be launching the global Cellenis brand in the U.S. and honored to partner with Estar Medical,” Dowell says. “These innovative biologic products, combined with our line of best-in-class medical devices, will build upon our promise to deliver optimal patient outcomes to our practitioners.”